Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:AIM
DateTimeSourceHeadlineSymbolCompany
06/10/20247:55AMGlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Pitch ConferenceAMEX:AIMAIM ImmunoTech Inc
06/03/20249:15AMEdgar (US Regulatory)Form 8-K - Current reportAMEX:AIMAIM ImmunoTech Inc
06/03/20249:05AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:AIMAIM ImmunoTech Inc
06/03/20248:15AMGlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesAMEX:AIMAIM ImmunoTech Inc
05/31/20247:30AMGlobeNewswire Inc.AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct OfferingAMEX:AIMAIM ImmunoTech Inc
05/31/20247:14AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:AIMAIM ImmunoTech Inc
05/20/20248:15AMGlobeNewswire Inc.AIM ImmunoTech to Participate in Two Upcoming Investor ConferencesAMEX:AIMAIM ImmunoTech Inc
05/16/20246:30AMGlobeNewswire Inc.AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
05/15/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:AIMAIM ImmunoTech Inc
05/09/20247:50AMGlobeNewswire Inc.AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
05/07/20247:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/07/20247:30AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:AIMAIM ImmunoTech Inc
05/06/20247:30AMGlobeNewswire Inc.AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®AMEX:AIMAIM ImmunoTech Inc
04/29/20247:55AMGlobeNewswire Inc.AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerAMEX:AIMAIM ImmunoTech Inc
04/25/20247:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/18/20247:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/15/20247:55AMGlobeNewswire Inc.AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsAMEX:AIMAIM ImmunoTech Inc
04/11/202410:00AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
04/10/20247:21AMGlobeNewswire Inc.AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerAMEX:AIMAIM ImmunoTech Inc
04/02/20246:30AMGlobeNewswire Inc.AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateAMEX:AIMAIM ImmunoTech Inc
03/28/20247:05AMGlobeNewswire Inc.AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceAMEX:AIMAIM ImmunoTech Inc
03/26/20248:05AMGlobeNewswire Inc.AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastAMEX:AIMAIM ImmunoTech Inc
03/25/20248:05AMGlobeNewswire Inc.AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchAMEX:AIMAIM ImmunoTech Inc
03/22/20247:55AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
03/20/20248:25AMGlobeNewswire Inc.AIM ImmunoTech Announces Release of the Next CEO Corner SegmentAMEX:AIMAIM ImmunoTech Inc
03/15/20247:45AMGlobeNewswire Inc.AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityAMEX:AIMAIM ImmunoTech Inc
03/07/20247:45AMGlobeNewswire Inc.AIM ImmunoTech Announces Launch of CEO Corner PlatformAMEX:AIMAIM ImmunoTech Inc
02/29/20247:45AMGlobeNewswire Inc.AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateAMEX:AIMAIM ImmunoTech Inc
02/21/20249:37AMEdgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]AMEX:AIMAIM ImmunoTech Inc
02/20/20243:34PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:AIMAIM ImmunoTech Inc
 Showing the most relevant articles for your search:AMEX:AIM